1. Volume 34, Pages 122-130 (August 2017)
Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – Results from the prospective German TMK cohort study 
Thomas Fietz, Hans Tesch, Jacqueline Rauh, Emil Boller, Lisa Kruggel, Martina Jänicke, Norbert Marschner 
The Breast 
Volume 34, Pages (August 2017)
DOI: /j.breast
Copyright © 2017 The Author(s) Terms and Conditions

2. Fig. 1
Cohort definition for the treatment reality data. Number of patients enrolled in the TMK, according to their tumour subtype and the palliative first-line therapy. Triple negative: negative for HR and HER2. Abbreviations: HR, hormone receptor; HER2, human epidermal growth factor receptor 2.
The Breast  , DOI: ( /j.breast )
Copyright © 2017 The Author(s) Terms and Conditions

3. Fig. 2
Chemotherapy regimens per year – palliative first-line. (A–C) First-line chemotherapy regimens sorted by absolute frequency in (A) HR-positive/HER2-negative patients (n = 430), (B) HER2-positive (n = 362) and (C) triple negative patients (n = 198). (D) Percentage of treatments containing taxanes (docetaxel or paclitaxel), sorted by tumour subtype. (E) Percentage of single-agent chemotherapies with or without targeted therapy, sorted by tumour subtype. Abbreviations: Bev, bevacizumab; C, cyclophosphamide; Cap, capecitabine; Car, carboplatin; D, docetaxel; E/A, epirubicin or doxorubicin; Gem, gemcitabin; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; P, paclitaxel; Per, pertuzumab; Tra, trastuzumab; Vin, vinorelbine.
The Breast  , DOI: ( /j.breast )
Copyright © 2017 The Author(s) Terms and Conditions

4. Fig. 3
Endocrine therapy regimens per year – palliative first-line. First-line endocrine regimens sorted by absolute frequency in patients with (A) HR-positive/HER2-negative tumours (n = 324) and (B) HR-positive/HER2-positive tumours (n = 81). In total, 51% of the patients with HR-positive/HER2-positive tumours received an additional trastuzumab therapy. Abbreviations: HER2, human epidermal growth factor receptor 2; HR, hormone receptor; Tra, trastuzumab.
The Breast  , DOI: ( /j.breast )
Copyright © 2017 The Author(s) Terms and Conditions

5. Fig. 4
Systemic treatment regimens per year – palliative second-line. (A–C) Second-line chemotherapy regimens (Top 5) sorted by absolute frequency in (A) patients with HR-positive/HER2-negative (n = 216), (B) HER2-positive (n = 180) or (C) triple negative tumours (n = 104). (D) Percentage of treatments containing taxanes (docetaxel or paclitaxel), sorted by tumour subtype. (E–F) Employed second-line endocrine regimens (Top 5) sorted by absolute frequency in (E) patients with HR-positive/HER2-negative or (F) HR-positive/HER2-positive tumours. In total, 24% of the patients with HR-positive/HER2-positive tumours received an additional trastuzumab therapy. Abbreviations: Bev, bevacizumab; C, cyclophosphamid; Cap, capecitabine; E/A, epirubicin or doxorubicin; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; Lap, lapatinib; P, paclitaxel; T-DM1, trastuzumab-emtansin; Tra, trastuzumab; Vin, vinorelbine.
The Breast  , DOI: ( /j.breast )
Copyright © 2017 The Author(s) Terms and Conditions

6. Fig. 5
Cohort definition for the outcome data. Number of patients enrolled in the TMK starting first-line therapy until December 31, 2012; split up according to the tumour subtype. Triple negative: negative for HR and HER2. Abbreviations: HR, hormone receptor; HER2, human epidermal growth factor receptor 2.
The Breast  , DOI: ( /j.breast )
Copyright © 2017 The Author(s) Terms and Conditions

7. Fig. 6
Number of palliative treatment lines. Percentage of patients receiving palliative treatment lines. Depicted are patients with (A) HR-positive/HER2-negative tumours (n = 445), (B) HR-positive/HER2-positive tumours (n = 186), (C) HR-negative/HER2-positive tumours (n = 92) and (D) triple negative tumours (n = 117). All patients starting first-line therapy until December 31, 2012 were included in this analysis (see Fig. 5). Potential: further treatment possible (current line ongoing, therapy paused or documentation finished).
The Breast  , DOI: ( /j.breast )
Copyright © 2017 The Author(s) Terms and Conditions

8. Fig. 7
Overall survival of patients with advanced breast cancer. All patients starting first-line therapy until December 31, 2012 were included (see Fig. 4). The exact date of death was unknown for three patients; therefore they were excluded from this analysis. HR-positive/HER2-negative, n = 443; HER2-positive, n = 277; triple negative, n = 117. Abbreviations: pos., positive; neg., negative; CI, confidence interval.
The Breast  , DOI: ( /j.breast )
Copyright © 2017 The Author(s) Terms and Conditions